Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care
Psyence Biomedical Ltd. (NASDAQ:PBM) announced a major milestone on Monday with the initiation of the first clinical trial site in Australia for its Phase IIb study on nature-derived psilocybin as a potential treatment for Adjustment Disorder in patients receiving palliative care. This development marks a key step toward advancing psychedelic-based treatments in the healthcare industry.
The trial, conducted in partnership with Fluence, a leader in psychedelic therapy research, and iNGENū CRO Pty Ltd, a renowned Australian clinical research organization, aims to explore the efficacy of Psyence’s naturally sourced psilocybin drug, PEX010. As the company stated, patient screening is set …